| Year |
Citation |
Score |
| 2022 |
Hendrix N, Oestreicher N, Lalla D, Dolan CM, Fisher KA, Veenstra DL, Moy B. Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clinical Breast Cancer. PMID 36220724 DOI: 10.1016/j.clbc.2022.08.012 |
0.606 |
|
| 2021 |
Hendrix N, Veenstra DL, Cheng M, Anderson NC, Verguet S. Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 25: 331-339. PMID 35227443 DOI: 10.1016/j.jval.2021.08.015 |
0.533 |
|
| 2020 |
Neuberger EE, Carlson JJ, Veenstra DL. Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome. Pharmacoeconomics. PMID 32715412 DOI: 10.1007/S40273-020-00945-Z |
0.337 |
|
| 2020 |
Dhanda DS, Veenstra DL, Regier DA, Basu A, Carlson JJ. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. Journal of Managed Care & Specialty Pharmacy. 26: 529-537. PMID 32223606 DOI: 10.18553/Jmcp.2020.26.4.529 |
0.391 |
|
| 2020 |
Veenstra DL, Mandelblatt J, Neumann P, Basu A, Peterson JF, Ramsey SD. Health Economics Tools and Precision Medicine: Opportunities and Challenges. Forum For Health Economics & Policy. PMID 32134729 DOI: 10.1515/Fhep-2019-0013 |
0.351 |
|
| 2020 |
Basu A, Carlson J, Veenstra D. Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 23: 96-103. PMID 31952678 DOI: 10.1016/J.Jval.2019.10.014 |
0.32 |
|
| 2019 |
Guzauskas GF, Basu A, Carlson JJ, Veenstra DL. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 988-994. PMID 31511188 DOI: 10.1016/J.Jval.2019.03.023 |
0.313 |
|
| 2019 |
Niu X, Amendola LM, Hart R, Bennette CS, Heagerty P, Horike-Pyne M, Trinidad SB, Rosenthal EA, Comstock B, Nefcy C, Hisama FM, Bennett RL, Grady WM, Gallego CJ, Tarczy-Hornoch P, ... ... Veenstra DL, et al. Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study. Contemporary Clinical Trials. 84: 105820. PMID 31400517 DOI: 10.1016/J.Cct.2019.105820 |
0.357 |
|
| 2019 |
Veenstra DL, Guzauskas G, Peterson J, Hassen DA, Snyder S, Hao J, Williams M. Cost-effectiveness of population genomic screening. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31303645 DOI: 10.1038/S41436-019-0580-4 |
0.332 |
|
| 2019 |
Li M, Basu A, Bennette C, Veenstra D, Garrison LP. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 777-784. PMID 31277824 DOI: 10.1016/J.Jval.2019.02.002 |
0.358 |
|
| 2019 |
Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Economics. 28: 855-867. PMID 31237095 DOI: 10.1002/Hec.3899 |
0.307 |
|
| 2019 |
Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 31089966 DOI: 10.1007/S40273-019-00809-1 |
0.644 |
|
| 2019 |
Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. Journal of Genetic Counseling. 28: 477-490. PMID 30964586 DOI: 10.1007/S10897-018-0286-9 |
0.312 |
|
| 2019 |
Guzauskas GF, Masaquel A, Thuresson PO, Dawson K, Veenstra DL. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leukemia & Lymphoma. 1-9. PMID 30632837 DOI: 10.1080/10428194.2018.1551532 |
0.34 |
|
| 2019 |
Spencer S, Veenstra DL, Guzauskas G. Pcv58 Cost-Effectiveness Of Population-Wide Genomic Screening For Familial Hypercholesterolemia Value in Health. 22. DOI: 10.1016/J.Jval.2019.04.494 |
0.318 |
|
| 2019 |
Guzauskas G, Spencer S, Veenstra DL. Ppm5 Timing And The Cost-Effectiveness Of Population-Wide Genomic Screening For Breast And Ovarian Cancer Value in Health. 22. DOI: 10.1016/J.Jval.2019.04.1628 |
0.322 |
|
| 2018 |
Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. Journal of Managed Care & Specialty Pharmacy. 24: 1210-1217. PMID 30479197 DOI: 10.18553/Jmcp.2018.24.12.1210 |
0.306 |
|
| 2018 |
Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, Biswas S, Bowling KM, Brothers KB, Conlin LK, Cooper GM, Dulik MC, East KM, Everett JN, Finnila CR, ... ... Veenstra DL, et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 30287922 DOI: 10.1038/S41436-018-0308-X |
0.337 |
|
| 2018 |
Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 30194623 DOI: 10.1007/S40273-018-0709-3 |
0.662 |
|
| 2018 |
Amendola LM, Berg JS, Horowitz CR, Angelo F, Bensen JT, Biesecker BB, Biesecker LG, Cooper GM, East K, Filipski K, Fullerton SM, Gelb BD, Goddard KAB, Hailu B, Hart R, ... ... Veenstra DL, et al. The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations. American Journal of Human Genetics. 103: 319-327. PMID 30193136 DOI: 10.1016/J.Ajhg.2018.08.007 |
0.321 |
|
| 2018 |
Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD. Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Medicine. PMID 30030904 DOI: 10.1002/Cam4.1657 |
0.308 |
|
| 2018 |
Weymann D, Veenstra DL, Jarvik GP, Regier DA. Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment. European Journal of Human Genetics : Ejhg. PMID 29802320 DOI: 10.1038/S41431-018-0161-Z |
0.376 |
|
| 2017 |
Carlson JJ, Kim D, Guzauskas GF, Bennette CS, Hershman DL, Baker LH, Hendrix N, Basu A, Veenstra DL, Ramsey S. Impact of value of research analyses on SWOG’s clinical trial capsule scoring. Journal of Clinical Oncology. 35: e18311-e18311. DOI: 10.1200/Jco.2017.35.15_Suppl.E18311 |
0.301 |
|
| 2017 |
Guzauskas GF, Masaquel A, Thuresson P, Li J, Reyes CM, Veenstra D. Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US? Blood. 130: 5603-5603. DOI: 10.1182/Blood.V130.Suppl_1.5603.5603 |
0.371 |
|
| 2016 |
Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. Journal of Managed Care & Specialty Pharmacy. 22: 939-47. PMID 27459657 DOI: 10.18553/Jmcp.2016.22.8.939 |
0.304 |
|
| 2016 |
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Veenstra DL, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. PMID 27181682 DOI: 10.1016/J.Ajhg.2016.04.011 |
0.336 |
|
| 2016 |
Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Medical Decision Making : An International Journal of the Society For Medical Decision Making. PMID 27012232 DOI: 10.1177/0272989X16636847 |
0.31 |
|
| 2016 |
Guzauskas GF, Masaquel A, Reyes C, Wilhelm K, Krivasi T, Veenstra DL. What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US? Blood. 128: 3605-3605. DOI: 10.1182/Blood.V128.22.3605.3605 |
0.341 |
|
| 2016 |
Veenstra DL. The value of routine pharmacogenomic screening - Are we there yet? A perspective on the costs and benefits of routine screening - Shouldn't everyone have this done? Clinical Pharmacology and Therapeutics. 99: 164-166. DOI: 10.1002/Cpt.299 |
0.392 |
|
| 2015 |
Gallego CJ, Perez ML, Burt A, Amendola LM, Shirts BH, Pritchard CC, Hisama FM, Bennett RL, Veenstra DL, Jarvik GP. Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome. Journal of Genetic Counseling. PMID 26637299 DOI: 10.1007/S10897-015-9902-0 |
0.371 |
|
| 2015 |
Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra DL. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). Journal of Managed Care & Specialty Pharmacy. 21: 700-12. PMID 26233542 DOI: 10.18553/Jmcp.2015.21.8.700 |
0.33 |
|
| 2015 |
Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2084-91. PMID 25940718 DOI: 10.1200/Jco.2014.59.3665 |
0.352 |
|
| 2015 |
Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. Journal of Managed Care & Specialty Pharmacy. 21: 269-75. PMID 25803760 DOI: 10.18553/Jmcp.2015.21.4.269 |
0.332 |
|
| 2015 |
Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 587-95. PMID 25394171 DOI: 10.1038/Gim.2014.156 |
0.343 |
|
| 2015 |
Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 149-55. PMID 25332254 DOI: 10.1200/Jco.2014.55.5409 |
0.307 |
|
| 2015 |
Williams JK, Cashion AK, Veenstra DL. Challenges in evaluating next-generation sequence data for clinical decisions. Nursing Outlook. 63: 48-50. PMID 25261386 DOI: 10.1016/J.Outlook.2014.08.007 |
0.344 |
|
| 2015 |
Bennette CS, Ramsey SD, Veenstra DL, Basu A, Carlson JJ. Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group. Journal of Clinical Oncology. 33: 6506-6506. DOI: 10.1200/Jco.2015.33.15_Suppl.6506 |
0.323 |
|
| 2014 |
Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, ... ... Veenstra DL, et al. Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemporary Clinical Trials. 39: 1-8. PMID 24997220 DOI: 10.1016/J.Cct.2014.06.016 |
0.39 |
|
| 2014 |
Veenstra DL, Reyes CM, Ramsey SD. Is obinutuzumab cost-effective in the first-line treatment of CLL? Journal of Clinical Oncology. 32: 7052-7052. DOI: 10.1200/Jco.2014.32.15_Suppl.7052 |
0.38 |
|
| 2014 |
Reyes C, Gazauskas G, Becker U, Moreno S, Veenstra DL. Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Blood. 124: 1324-1324. DOI: 10.1182/Blood.V124.21.1324.1324 |
0.374 |
|
| 2014 |
Guzauskas GF, Villa KF, Vanhove TF, Veenstra DL. Risk-Benefit Trade-Off of Pediatric-Inspired Versus Hyper-CVAD Protocols for Philadelphia Negative Acute Lymphocytic Leukemia (ALL) in Adolescents and Young Adults: A Modeling Analysis Blood. 124: 1281-1281. DOI: 10.1182/Blood.V124.21.1281.1281 |
0.313 |
|
| 2013 |
Towse A, Ossa D, Veenstra D, Carlson J, Garrison L. Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. Journal of Personalized Medicine. 3: 288-305. PMID 25562729 DOI: 10.3390/Jpm3040288 |
0.383 |
|
| 2013 |
Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. Pharmacogenomics. 14: 869-83. PMID 23746182 DOI: 10.2217/Pgs.13.74 |
0.341 |
|
| 2013 |
Feero WG, Wicklund C, Veenstra DL. The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. Jama. 309: 1235-6. PMID 23532238 DOI: 10.1001/Jama.2013.113 |
0.322 |
|
| 2013 |
Calonge N, Fisher NL, Berg AO, Campos-Outcalt D, Djulbegovic B, Ganiats TG, Haddow JE, Klein RD, Lyman DO, Offit K, Pauker SG, Piper M, Richards CS, Strickland OL, Tunis SR, ... Veenstra DL, et al. Recommendations from the EGAPP Working Group: Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genetics in Medicine. 15: 517-527. PMID 23429431 DOI: 10.1038/Gim.2012.184 |
0.336 |
|
| 2013 |
Ramsey SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemporary Clinical Trials. 34: 1-9. PMID 23000081 DOI: 10.1016/J.Cct.2012.09.003 |
0.315 |
|
| 2013 |
Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 14-24. PMID 22955111 DOI: 10.1038/Gim.2012.106 |
0.322 |
|
| 2013 |
Veenstra DL, Bajaj PS, Carlson JJ, Goertz H. Is erlotinib for first-line use in EGFR+ non-small-cell lung cancer cost-effective? Journal of Clinical Oncology. 31: e19001-e19001. DOI: 10.1200/Jco.2013.31.15_Suppl.E19001 |
0.378 |
|
| 2013 |
McDermott C, Veenstra D, Hansen R, Sullivan S. The Value Of Improving Treatment Adherence In Chronic Hepatitis C Infectio Value in Health. 16: A214. DOI: 10.1016/J.Jval.2013.03.1086 |
0.306 |
|
| 2012 |
Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. Journal of the National Cancer Institute. 104: 1785-95. PMID 23197490 DOI: 10.1093/Jnci/Djs433 |
0.356 |
|
| 2012 |
Wong WB, Ramsey SD, Barlow WE, Garrison LP, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemporary Clinical Trials. 33: 1117-23. PMID 22981891 DOI: 10.1016/J.Cct.2012.08.006 |
0.338 |
|
| 2012 |
Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, Schully SD, Ramsey S, Tunis S, Freedman AN, Khoury MJ, Veenstra DL. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 14: 633-42. PMID 22516979 DOI: 10.1038/Gim.2012.16 |
0.334 |
|
| 2012 |
Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clinical Pharmacology and Therapeutics. 91: 829-37. PMID 22453194 DOI: 10.1038/Clpt.2011.303 |
0.336 |
|
| 2012 |
Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL. Systematic review of comparative effectiveness data for oncology orphan drugs. The American Journal of Managed Care. 18: 47-62. PMID 22435748 |
0.575 |
|
| 2012 |
Thariani R, Veenstra DL, Carlson JJ, Garrison LP, Ramsey S. Paying for personalized care: cancer biomarkers and comparative effectiveness. Molecular Oncology. 6: 260-6. PMID 22429896 DOI: 10.1016/J.Molonc.2012.02.006 |
0.411 |
|
| 2012 |
Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treatment Reviews. 38: 1004-11. PMID 22405931 DOI: 10.1016/J.Ctrv.2012.02.006 |
0.556 |
|
| 2012 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Potential cost-effectiveness of universal access to modern contraceptives in Uganda. Plos One. 7: e30735. PMID 22363480 DOI: 10.1371/Journal.Pone.0030735 |
0.368 |
|
| 2012 |
Branch KR, Bresnahan BW, Veenstra DL, Shuman WP, Weintraub WS, Busey JM, Elliott DJ, Mitsumori LM, Strote J, Jobe K, Dubinsky T, Caldwell JH. Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Academic Radiology. 19: 265-73. PMID 22209422 DOI: 10.1016/J.Acra.2011.10.029 |
0.341 |
|
| 2012 |
Blondon M, Righini M, Bounameaux H, Veenstra DL. Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. Chest. 141: 321-9. PMID 21757569 DOI: 10.1378/Chest.11-0625 |
0.363 |
|
| 2012 |
Thariani R, Blough DK, Barlow W, Henry NL, Gralow J, Ramsey SD, Veenstra DL. Evaluating the impact of a trial in breast cancer tumor markers: A value of research analysis. Journal of Clinical Oncology. 30: e16524-e16524. DOI: 10.1200/Jco.2012.30.15_Suppl.E16524 |
0.318 |
|
| 2011 |
Thariani R, Carlson JJ, Steuten L, Henry L, Gralow J, Ramsey S, Basu A, Veenstra DL. Evaluating a proposed swog trial of breast cancer tumor markers: A value of research and biobank analysis Medical Decision Making. 32. PMID 28071309 DOI: 10.1177/0272989X12439390 |
0.328 |
|
| 2011 |
Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH. How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Affairs (Project Hope). 30: 2259-68. PMID 22147853 DOI: 10.1377/Hlthaff.2010.0637 |
0.354 |
|
| 2011 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Estimating the costs of induced abortion in Uganda: a model-based analysis. Bmc Public Health. 11: 904. PMID 22145859 DOI: 10.1186/1471-2458-11-904 |
0.39 |
|
| 2011 |
Beitelshees AL, Veenstra DL. Evolving research and stakeholder perspectives on pharmacogenomics. Jama. 306: 1252-3. PMID 21934059 DOI: 10.1001/Jama.2011.1343 |
0.336 |
|
| 2011 |
Garrison LP, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. The Journal of Infectious Diseases. 204: S124-32. PMID 21666153 DOI: 10.1093/Infdis/Jir114 |
0.36 |
|
| 2011 |
Cross JT, Veenstra DL, Gardner JS, Garrison LP. Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. Clinical Pharmacology and Therapeutics. 89: 429-36. PMID 21289618 DOI: 10.1038/Clpt.2010.350 |
0.317 |
|
| 2011 |
Roth JA, Garrison LP, Burke W, Ramsey SD, Carlson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics. 14: 59-67. PMID 20407215 DOI: 10.1159/000290452 |
0.37 |
|
| 2010 |
Giovanni MA, Fickie MR, Lehmann LS, Green RC, Meckley LM, Veenstra D, Murray MF. Health-care referrals from direct-to-consumer genetic testing. Genetic Testing and Molecular Biomarkers. 14: 817-9. PMID 20979566 DOI: 10.1089/Gtmb.2010.0051 |
0.687 |
|
| 2010 |
Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 28: 1001-13. PMID 20936884 DOI: 10.2165/11537410-000000000-00000 |
0.433 |
|
| 2010 |
Veenstra DL, Roth JA, Garrison LP, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 12: 686-93. PMID 20808229 DOI: 10.1097/Gim.0B013E3181Eff533 |
0.367 |
|
| 2010 |
Cheng MM, Alfonso R, Best JH, Garrison LP, Bruhn D, Veenstra DL. The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. Journal of Medical Economics. 13: 193-202. PMID 20334490 DOI: 10.3111/13696991003757500 |
0.732 |
|
| 2010 |
Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 30: 328-40. PMID 20086232 DOI: 10.1177/0272989X09347014 |
0.349 |
|
| 2010 |
Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 19: 391-400. PMID 20084462 DOI: 10.1007/S11136-010-9589-5 |
0.624 |
|
| 2010 |
Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 28: 61-74. PMID 20014877 DOI: 10.2165/11318240-000000000-00000 |
0.701 |
|
| 2010 |
Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. Journal of Clinical Epidemiology. 63: 960-9. PMID 19995676 DOI: 10.1016/J.Jclinepi.2009.09.006 |
0.359 |
|
| 2009 |
Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 1118-23. PMID 19624617 DOI: 10.1111/J.1524-4733.2009.00572.X |
0.353 |
|
| 2009 |
Carlson JJ, Kowdley KV, Sullivan SD, Ramsey SD, Veenstra DL. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. Journal of Gastroenterology and Hepatology. 24: 786-91. PMID 19457153 DOI: 10.1111/J.1440-1746.2009.05778.X |
0.305 |
|
| 2009 |
Cheng MM, Lu B, Hu SS, Marelli C, Higashi MK, Patel PA, Li J, Veenstra DL. Optimizing CAD diagnosis in China with CT angiography. Journal of Cardiovascular Computed Tomography. 3: 153-8. PMID 19394919 DOI: 10.1016/J.Jcct.2009.03.005 |
0.752 |
|
| 2009 |
Veenstra D, Burke W. Pharmacogenomics and public health. Public Health Genomics. 12: 131-133. PMID 19204414 DOI: 10.1159/000189624 |
0.439 |
|
| 2009 |
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 20-7. PMID 18647257 DOI: 10.1111/J.1524-4733.2008.00415.X |
0.4 |
|
| 2008 |
Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thrombosis and Haemostasis. 100: 229-239. PMID 18690342 DOI: 10.1160/Th07-09-0552 |
0.679 |
|
| 2008 |
Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs. 68: 1105-13. PMID 18484801 DOI: 10.2165/00003495-200868080-00007 |
0.428 |
|
| 2008 |
Garrison LP, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metabolism Reviews. 40: 377-401. PMID 18464050 DOI: 10.1080/03602530801952500 |
0.671 |
|
| 2008 |
Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 131-8. PMID 18380625 DOI: 10.1111/J.1524-4733.2007.00221.X |
0.31 |
|
| 2008 |
Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Alimentary Pharmacology & Therapeutics. 27: 1240-1252. PMID 18373637 DOI: 10.1111/J.1365-2036.2008.03691.X |
0.32 |
|
| 2008 |
Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) Lung Cancer. 61: 405-415. PMID 18295368 DOI: 10.1016/J.Lungcan.2007.12.023 |
0.688 |
|
| 2008 |
Karuna ST, Thirlby R, Biehl T, Veenstra D. Cost-effectiveness of laparoscopy versus laparotomy for initial surgical evaluation and treatment of potentially resectable hepatic colorectal metastases: a decision analysis. Journal of Surgical Oncology. 97: 396-403. PMID 18270972 DOI: 10.1002/Jso.20964 |
0.344 |
|
| 2008 |
Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: Social and policy implications Pharmacogenomics Journal. 8: 85-89. PMID 17486108 DOI: 10.1038/Sj.Tpj.6500457 |
0.309 |
|
| 2008 |
Meckley L, Gudgeon J, Anderson J, Williams M, Veenstra D. PHP72 GENETIC TESTING FOR WARFARIN INITIATION: A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE Value in Health. 11: A51. DOI: 10.1016/S1098-3015(10)70170-4 |
0.72 |
|
| 2007 |
Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 9: 695-704. PMID 18073583 DOI: 10.1097/Gim.0B013E318156Dd07 |
0.385 |
|
| 2007 |
Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 25: 963-77. PMID 17960954 DOI: 10.2165/00019053-200725110-00006 |
0.333 |
|
| 2007 |
Sullivan SD, Veenstra DL, Chen PJ, Chang TT, Chuang WL, Tsai C, Patel K. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. Journal of Gastroenterology and Hepatology. 22: 1494-9. PMID 17716353 DOI: 10.1111/J.1440-1746.2006.04539.X |
0.306 |
|
| 2007 |
Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. European Journal of Gastroenterology & Hepatology. 19: 631-8. PMID 17625431 DOI: 10.1097/Meg.0B013E3281108079 |
0.323 |
|
| 2007 |
Carlson J, Oestreicher N, Lubeck DP, Ramsey SD, Veenstra DL. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 25: 7664-7664. DOI: 10.1200/Jco.2007.25.18_Suppl.7664 |
0.701 |
|
| 2007 |
Gudgeon J, Williams M, Anderson J, Meckley L, Veenstra D. PCASE10 SHOULD GENETIC TESTING BE USED TO GUIDE WARFARIN THERAPY? Value in Health. 10: A205-A206. DOI: 10.1016/S1098-3015(10)69150-4 |
0.682 |
|
| 2007 |
Meckley L, Austin M, Garrison L, Veenstra D. PCV56 THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY Value in Health. 10: A53. DOI: 10.1016/S1098-3015(10)68698-6 |
0.722 |
|
| 2006 |
Cohen AL, Veenstra D. Economic analysis of prevaccination serotesting compared with presumptive immunization for polio, diphtheria, and tetanus in internationally adopted and immigrant infants. Pediatrics. 117: 1650-5. PMID 16651319 DOI: 10.1542/Peds.2005-0822 |
0.301 |
|
| 2006 |
Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenetics and Genomics. 16: 139-47. PMID 16424826 DOI: 10.1097/01.Fpc.0000189801.96220.82 |
0.698 |
|
| 2005 |
Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 7: 519-23. PMID 16247290 DOI: 10.1097/01.Gim.0000182467.79495.E2 |
0.308 |
|
| 2005 |
Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 104: 2054-62. PMID 16216002 DOI: 10.1002/Cncr.21464 |
0.647 |
|
| 2005 |
Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genetics in Medicine : Official Journal of the American College of Medical Genetics. 7: 380-9. PMID 16024969 DOI: 10.1097/01.Gim.0000170776.31248.75 |
0.649 |
|
| 2005 |
Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ, Rettie AE. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clinical Pharmacology and Therapeutics. 77: 353-64. PMID 15900281 DOI: 10.1016/J.Clpt.2005.01.019 |
0.714 |
|
| 2005 |
Davis GE, Schwartz SR, Veenstra DL, Yueh B. Cost comparison of surgery vs organ preservation for laryngeal cancer. Archives of Otolaryngology--Head & Neck Surgery. 131: 21-6. PMID 15655180 DOI: 10.1001/Archotol.131.1.21 |
0.338 |
|
| 2005 |
Ramsey S, Veenstra D, Clarke L, Penson D, Gandhi S, Hirsch M. PCN14 IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH FLUTAMIDE? Value in Health. 8: 347-348. DOI: 10.1016/S1098-3015(10)62920-8 |
0.35 |
|
| 2004 |
Hu KK, Veenstra DL, Lipsky BA, Saint S. Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 39: 1441-5. PMID 15546079 DOI: 10.1086/425309 |
0.326 |
|
| 2004 |
Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics. 22: 481-93. PMID 15217305 DOI: 10.2165/00019053-200422080-00001 |
0.464 |
|
| 2004 |
Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de Boer A. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics. 14: 53-60. PMID 15128051 DOI: 10.1097/00008571-200401000-00006 |
0.377 |
|
| 2004 |
Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 22: 83-94. PMID 14731050 DOI: 10.2165/00019053-200422020-00002 |
0.755 |
|
| 2004 |
Meckley L, Veenstra D. SC4 ECONOMIC EVALUATION OF SCREENING FOR THE A-ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS Value in Health. 7: 228-229. DOI: 10.1016/S1098-3015(10)62093-1 |
0.679 |
|
| 2004 |
Oestreicher N, Veenstra D, Linden H, McCune J, Ramsey S. CE3 THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS: COMPARISON OF ATTRIBUTABLE COST AND MICROCOSTING APPROACHES Value in Health. 7: 226. DOI: 10.1016/S1098-3015(10)62085-2 |
0.67 |
|
| 2004 |
Salem L, Anaya D, Veenstra D, Sullivan S, Flum D. Timing of elective colectomy for diverticulitis: A modeled decision analysis Journal of the American College of Surgeons. 199: 69. DOI: 10.1016/J.Jamcollsurg.2004.05.148 |
0.381 |
|
| 2003 |
Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 764-71. PMID 12955636 DOI: 10.1086/377265 |
0.317 |
|
| 2003 |
Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. The American Journal of Managed Care. 9: 493-500. PMID 12866628 |
0.732 |
|
| 2003 |
Reed SD, Dillingham PW, Briggs AH, Veenstra DL, Sullivan SD. A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 23: 252-64. PMID 12809323 DOI: 10.1177/0272989X03023003007 |
0.397 |
|
| 2003 |
Phillips KA, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics. 4: 231-9. PMID 12718713 DOI: 10.1517/Phgs.4.3.231.22691 |
0.397 |
|
| 2003 |
Flum DR, Flowers C, Veenstra DL. A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. Journal of the American College of Surgeons. 196: 385-93. PMID 12648690 DOI: 10.1016/S1072-7515(02)01806-9 |
0.314 |
|
| 2003 |
Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. American Journal of Infection Control. 31: 1-8. PMID 12548250 DOI: 10.1067/Mic.2003.35 |
0.346 |
|
| 2002 |
Higashi MK, Veenstra DL, del Aguila M, Hujoel P. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. Journal of Periodontology. 73: 1474-84. PMID 12546098 DOI: 10.1902/Jop.2002.73.12.1474 |
0.742 |
|
| 2002 |
Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama. 287: 1690-8. PMID 11926893 DOI: 10.1001/Jama.287.13.1690 |
0.717 |
|
| 2002 |
Veenstra DL. The role of pharmacoeconomics in the genomics era Pharmaceutical News. 9: 21-26. |
0.34 |
|
| 2001 |
Devine EB, Kowdley KV, Veenstra DL, Sullivan SD. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 4: 376-84. PMID 11705128 DOI: 10.1046/J.1524-4733.2001.45075.X |
0.369 |
|
| 2001 |
Best JH, Veenstra DL, Geppert J. Trends in expenditures for Medicare liver transplant recipients. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 7: 858-62. PMID 11679983 DOI: 10.1053/Jlts.2001.27868 |
0.597 |
|
| 2001 |
Marciante KD, Gardner JS, Veenstra DL, Sullivan SD. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. American Journal of Public Health. 91: 1443-5. PMID 11527778 DOI: 10.2105/Ajph.91.9.1443 |
0.358 |
|
| 2001 |
Lee TA, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJK, Malinverni R, Pleil AM, Williamson T. Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS Pharmacoeconomics. 19: 535-550. PMID 11465299 DOI: 10.2165/00019053-200119050-00008 |
0.334 |
|
| 2000 |
Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. Aaps Pharmsci. 2: E29. PMID 11741245 DOI: 10.1208/Ps020329 |
0.767 |
|
| 2000 |
Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection Archives of Internal Medicine. 160: 2670-2675. PMID 10999983 DOI: 10.1001/Archinte.160.17.2670 |
0.36 |
|
| 2000 |
Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: Are antimicrobial catheters useful? Infection Control and Hospital Epidemiology. 21: 375-380. PMID 10879567 DOI: 10.1086/501776 |
0.314 |
|
| 2000 |
Veenstra DL, Higashi MK, Phillips KA. Assessing the comprehensiveness of pharmacogenomics Aaps Pharmsci. 2: 1-11. |
0.766 |
|
| 1999 |
Saint S, Veenstra DL, Sullivan SD. The use of meta-analysis in cost-effectiveness analysis issues and recommendations Pharmacoeconomics. 15: 1-8. PMID 10345156 DOI: 10.2165/00019053-199915010-00001 |
0.36 |
|
| 1999 |
Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 33: 829-39. PMID 10213637 DOI: 10.1016/S0272-6386(99)70414-2 |
0.6 |
|
| 1999 |
Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and cost of steroid side effects after renal transplantation. Transplantation Proceedings. 31: 301-2. PMID 10083116 DOI: 10.1016/S0041-1345(98)01635-2 |
0.608 |
|
| 1998 |
Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. THE INCIDENCE AND COSTS OF STEROID-RELATED SIDE EFFECTS IN RENAL TRANSPLANTATION Transplantation. 65: 132. DOI: 10.1097/00007890-199805131-00214 |
0.609 |
|
| Show low-probability matches. |